LifeCycle Pharma A/S to Host Conference Call Announcing Interim Report for 1st Quarter 2010 - results from January 1 to March 31, 2010

Investor Service Announcement no. 2/2010			                                     

To: NASDAQ OMX Copenhagen           	Hørsholm, Denmark, May 7, 2010 



            LifeCycle Pharma A/S to Host Conference Call Announcing             
 Interim Report for 1st Quarter 2010 - results from January 1 to March 31, 2010 

LifeCycle Pharma A/S (OMX: LCP) will announce the Interim Report for 1st Quarter
2010 on Wednesday May 12, 2010 after 05:00 PM. LCP's Executive Management will  
host an accompanying conference call to discuss the financial results on        
Wednesday May 12, 2010 at 05:30 PM CET (Denmark); 04:30 GMT (London), 11:30 AM  
ET (New York), 08:30 AM PT (San Francisco).                                     

To access the live conference call, please dial one of the following numbers:   
+45 32 71 47 75       (Denmark) Toll                                      
+1 212 444 0481       (USA) Toll                                           
+44 (0)20 7136 2051   (UK) Toll                                               

An call audio replay of the conference will be available on www.lcpharma.com    
from Thursday, May 13, 2010 at 18:00 CET (Denmark); 17:00 GMT (London), 12:00 PM
ET (New York), 09:00 AM PT (San Francisco), through Friday, June 11, 2010 by    
dialing +45 32 71 09 13 (DK), +44 (0) 20 7111 1244 (UK) or +1 347 366 9565 (US),
and entering access code 2534991#.                                              


For more information, please contact:                                           
Dr. William J. Polvino                or   Peter Schøtt Knudsen 
President & Chief Executive Officer        Head of Investor Relations
Phone: + 45 7033 3300                      Phone: + 45 2055 3817
Email: WJP@lcpharma.com                    Email: PSK@lcpharma.com				 


	                                                                               
About LifeCycle Pharma A/S (LCP)                                                
Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging      
specialty pharmaceutical company. Clinical development is the core of LCP's     
effort to develop a product portfolio which includes products for               
immunosuppression, specifically organ transplantation, and products to combat   
certain cardiovascular diseases. As a fully integrated company, LCP adapts new  
technologies on a fast commercial timetable. LCP's unique, patented delivery    
technology, MeltDose®, can improve absorption and bioavailability - at low-scale
up costs - not only for a broad spectrum of drugs already on the market, but    
also for new chemical entities. LCP has a cholesterol-lowering product,         
Fenoglide®, currently on the U.S. market and a diversified near- and medium-term
pipeline with four product candidates in clinical trials and a number of        
projects in preclinical development. LCP is listed on the NASDAQ OMX Copenhagen 
under the trading symbol (OMX: LCP).                                            

For further information, please visit www.lcpharma.com.